II 

108TH CONGRESS 

1ST SESSION S. 1780

To amend the Controlled Substances Act to clarify the definition of anabolic 

steroids and to provide for research and education activities relating 

to steroids and steroid precursors. 

IN THE SENATE OF THE UNITED STATES 

OCTOBER 23, 2003

Mr. BIDEN (for himself, Mr. HATCH, Mr. GRASSLEY, and Mr. HARKIN) introduced the following bill; which was read twice and referred to the Committee on the Judiciary 

A BILL

To amend the Controlled Substances Act to clarify the definition of anabolic steroids and to provide for research 

and education activities relating to steroids and steroid 

precursors.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Anabolic Steroid Con5 trol Act of 2003’’. 
2

•S 1780 IS 

1 SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 

2 ACT. 

3 (a) DEFINITIONS.—Section 102 of the Controlled 

4 Substances Act (21 U.S.C. 802) is amended—

5 (1) in paragraph (41)—

6 (A) by realigning the margin so as to align 

7 with paragraph (40); 

8 (B) by striking subparagraph (A) and in9 serting the following: 

10 ‘‘(A) The term ‘anabolic steroid’ means any drug or 

11 hormonal substance, chemically and pharmacologically re12 lated to testosterone (other than estrogens, progestins, 

13 corticosteroids, and dehydroepiandrosterone), and in14 cludes—

15 ‘‘(i) androstanediol—

16 ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 

17 ‘‘(II) 3α,17β-dihydroxy-5α-androstane; 

18 ‘‘(ii) androstanedione (5α-androstan-3,17-

19 dione); 

20 ‘‘(iii) androstenediol—

21 ‘‘(I) 1-androstenediol (3β,17β-dihydroxy22 5α-androst-1-ene); 

23 ‘‘(II) 1-androstenediol (3α,17β-dihydroxy24 5α-androst-1-ene); 

25 ‘‘(III) 4-androstenediol (3β,17β-dihydroxy26 androst-4-ene); and 
3

•S 1780 IS 

1 ‘‘(IV) 5-androstenediol (3b,17β-dihydroxy2 androst-5-ene); 

3 ‘‘(iv) androstenedione—

4 ‘‘(I) 1-androstenedione ([5α]-androst-1-en5 3,17-dione); 

6 ‘‘(II) 4-androstenedione (androst-4-en7 3,17-dione); and 

8 ‘‘(III) 5-androstenedione (androst-5-en9 3,17-dione); 

10 ‘‘(v) bolasterone (7α,17α-dimethyl-17β11 hydroxyandrost-4-en-3-one); 

12 ‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene13 3-one); 

14 ‘‘(vii) calusterone (7β,17α-dimethyl-17β15 hydroxyandrost-4-en-3-one); 

16 ‘‘(viii) clostebol (4-chloro-17β-hydroxyandrost-4-

17 en-3-one); 

18 ‘‘(ix) dehydrochlormethyltestosterone (4-chloro19 17β-hydroxy-17α-methyl-androst-1,4-dien-3-one); 

20 ‘‘(x) 4-dihydrotestosterone (17β-hydroxy21 androstan-3-one); 

22 ‘‘(xi) drostanolone (17β-hydroxy-2α-methyl-5α23 androstan-3-one); 

24 ‘‘(xii) ethylestrenol (17α-ethyl-17β-hydroxyestr25 4-ene); 
4

•S 1780 IS 

1 ‘‘(xiii) fluoxymesterone (9-fluoro-17α-methyl2 11β,17β-dihydroxyandrost-4-en-3-one); 

3 ‘‘(xiv) formebolone (2-formyl-17α-methyl4 11α,17β-dihydroxyandrost-1,4-dien-3-one); 

5 ‘‘(xv) furazabol (17α-methyl-17β6 hydroxyandrostano[2,3-c]-furazan); 

7 ‘‘(xvi) 18α-homo-17β-hydroxyestr-4-en-3-one 

8 (13β-ethyl-17β-hydroxygon-4-en-3-one); 

9 ‘‘(xvii) 4-hydroxytestosterone (4,17β-dihydroxy10 androst-4-en-3-one); 

11 ‘‘(xviii) 4-hydroxy-19-nortestosterone (4,17β12 dihydroxy-estr-4-en-3-one); 

13 ‘‘(xix) mestanolone (17α-methyl-17β-hydroxy14 5α-androstan-3-one); 

15 ‘‘(xx) mesterolone (1α-methyl-17β-hydroxy16 [5α]-androstan-3-one); 

17 ‘‘(xxi) methandienone (17α-methyl-17β18 hydroxyandrost-1,4-dien-3-one); 

19 ‘‘(xxii) methandriol (17α-methyl-3β,17β20 dihydroxyandrost-5-ene); 

21 ‘‘(xxiii) methenolone (1-methyl-17β-hydroxy-5α22 androst-1-en-3-one); 

23 ‘‘(xxiv) methyltestosterone (17α-methyl-17β24 hydroxyandrost-4-en-3-one); 
5

•S 1780 IS 

1 ‘‘(xxv) mibolerone (7α,17α-dimethyl-17β2 hydroxyestr-4-en-3-one); 

3 ‘‘(xxvi) nandrolone (17β-hydroxyestr-4-en-3-

4 one); 

5 ‘‘(xxvii) norandrostenediol—

6 ‘‘(I) 19-nor-4-androstenediol (3β, 17β7 dihydroxyestr-4-ene); 

8 ‘‘(II) 19-nor-4-androstenediol (3α, 17β9 dihydroxyestr-4-ene); 

10 ‘‘(III) 19-nor-5-androstenediol (3β, 17β11 dihydroxyestr-5-ene); and 

12 ‘‘(IV) 19-nor-5-androstenediol (3α, 17β13 dihydroxyestr-5-ene); 

14 ‘‘(xxviii) norandrostenedione—

15 ‘‘(I) 19-nor-4-androstenedione (estr-4-en16 3,17-dione); and 

17 ‘‘(II) 19-nor-5-androstenedione (estr-5-en18 3,17-dione; 

19 ‘‘(xxix) norbolethone (18α-homo-17β20 hydroxypregna-4-en-3-one); 

21 ‘‘(xxx) norclostebol (4-chloro-17β-hydroxyestr-4-

22 en-3-one); 

23 ‘‘(xxxi) norethandrolone (17α-ethyl-17β24 hydroxyestr-4-en-3-one); 
6

•S 1780 IS 

1 ‘‘(xxxii) oxandrolone (17α-methyl-17β-hydroxy2 2-oxa-[5α]-androstan-3-one);

3 ‘‘(xxxiii) oxymesterone (17α-methyl-4,17β4 dihydroxyandrost-4-en-3-one); 

5 ‘‘(xxxiv) oxymetholone (17α-methyl-2-

6 hydroxymethylene-17β-hydroxy-[5α]-androstan-3-

7 one); 

8 ‘‘(xxxv) stanozolol (17α-methyl-17β-hydroxy9 [5α]-androst-2-eno[3,2-c]-pyrazole); 

10 ‘‘(xxxvi) stenbolone (17β-hydroxy-2-methyl11 [5α]-androst-1-en-3-one); 

12 ‘‘(xxxvii) testolactone (13-hydroxy-3-oxo-13,17-

13 secoandrosta-1,4-dien-17-oic acid lactone); 

14 ‘‘(xxxviii) 1-testosterone (17β-hydroxy-5α15 androst-1-en-3-one); 

16 ‘‘(xxxix) testosterone (17β-hydroxyandrost-4-en17 3-one); 

18 ‘‘(xl) tetrahydrogestrinone (13β,17α-diethyl19 17β-hydroxygon-4,9,11-trien-3-one); 

20 ‘‘(xli) trenbolone (17β-hydroxyestr-4,9,11-trien21 3-one); and 

22 ‘‘(xlii) any salt, ester, or ether of a drug or sub23 stance described in this paragraph.’’; and 

24 (C) by adding at the end the following: 
7

•S 1780 IS 

1 ‘‘(C) Notwithstanding subparagraph (A), the Attor2 ney General may not schedule Androstenedione as a con3 trolled substance in accordance with this Act until the At4 torney General receives a finding from the Commissioner 

5 of Food and Drugs relating to whether Androstenedione 

6 is lawfully marketed under the Federal Food, Drug, and 

7 Cosmetic Act (21 U.S.C. 321 et seq.).’’; and 

8 (2) in paragraph (44), by inserting ‘‘anabolic 

9 steroids,’’ after ‘‘marihuana,’’. 

10 (b) AUTHORITY AND CRITERIA FOR CLASSIFICA11 TION.—Section 201(g) of the Controlled Substances Act 

12 (21 U.S.C. 811(g)) is amended—

13 (1) in paragraph (1), by striking ‘‘substance 

14 from a schedule if such substance’’ and inserting 

15 ‘‘drug which contains a controlled substance from 

16 the application of titles II and III of the Comprehen17 sive Drug Abuse Prevention and Control Act (21 

18 U.S.C. 802 et seq.) if such drug’’; and 

19 (2) in paragraph (3), by adding at the end the 

20 following: 

21 ‘‘(C) Upon the recommendation of the Sec22 retary of Health and Human Services, a compound, 

23 mixture, or preparation which contains any anabolic 

24 steroid, which is intended for administration to a 

25 human being or an animal, and which, because of its 
8

•S 1780 IS 

1 concentration, preparation, formulation or delivery 

2 system, does not present any significant potential for 

3 abuse.’’. 

4 (c) ANABOLIC STEROIDS CONTROL ACT.—Section 

5 1903 of the Anabolic Steroids Control Act of 1990 (Public 

6 Law 101–647) is amended—

7 (1) by striking subsection (a); and 

8 (2) by redesignating subsections (b) and (c) as 

9 subsections (a) and (b), respectively. 

10 SEC. 3. SENTENCING COMMISSION GUIDELINES. 

11 The United States Sentencing Commission shall—

12 (1) review the Federal sentencing guidelines 

13 with respect to offenses involving anabolic steroids; 

14 (2) consider amending the Federal sentencing 

15 guidelines to provide for increased penalties with re16 spect to offenses involving anabolic steroids in a 

17 manner that reflects the seriousness of such offenses 

18 and the need to deter anabolic steroid use; and 

19 (3) take such other action that the Commission 

20 considers necessary to carry out this section. 

21 SEC. 4. PREVENTION AND EDUCATION PROGRAMS. 

22 (a) IN GENERAL.—The Secretary of Health and 

23 Human Services (referred to in this Act as the ‘‘Sec24 retary’’) shall award grants to public and nonprofit private 

25 entities to enable such entities to carry out science-based 
9

•S 1780 IS 

1 education programs in elementary and secondary schools 

2 to highlight the harmful effects of anabolic steroids. 

3 (b) ELIGIBILITY.—

4 (1) APPLICATION.—To be eligible for grants 

5 under subsection (a), an entity shall prepare and 

6 submit to the Secretary an application at such time, 

7 in such manner, and containing such information as 

8 the Secretary may require. 

9 (2) PREFERENCE.—In awarding grants under 

10 subsection (a), the Secretary shall give preference to 

11 applicants that intend to use grant funds to carry 

12 out programs based on—

13 (A) the Athletes Training and Learning to 

14 Avoid Steroids program; 

15 (B) the Athletes Targeting Healthy Exer16 cise and Nutrition Alternatives program; and 

17 (C) other programs determined to be effec18 tive by the National Institute on Drug Abuse. 

19 (c) USE OF FUNDS.—Amounts received under a 

20 grant under subsection (a) shall be used primarily for edu21 cation programs that will directly communicate with 

22 teachers, principals, coaches, as well as elementary and 

23 secondary school children concerning the harmful effects 

24 of anabolic steroids. 
10

•S 1780 IS 

1 (d) AUTHORIZATION OF APPROPRIATIONS.—There is 

2 authorized to be appropriated to carry out this section, 

3 $15,000,000 for each of fiscal years 2004 through 2009. 

4 SEC. 5. NATIONAL SURVEY ON DRUG USE AND HEALTH. 

5 (a) IN GENERAL.—The Secretary of Health and 

6 Human Services shall ensure that the National Survey on 

7 Drug Use and Health includes questions concerning the 

8 use of anabolic steroids. 

9 (b) AUTHORIZATION OF APPROPRIATIONS.—There is 

10 authorized to be appropriated to carry out this section, 

11 $1,000,000 for each of fiscal years 2004 through 2009.

Æ